Show simple item record

dc.contributor.authorWong, Ting Y
dc.contributor.authorLee, Katherine S
dc.contributor.authorRuss, Brynnan P
dc.contributor.authorHorspool, Alexander M
dc.contributor.authorKang, Jason
dc.contributor.authorWinters, Michael T
dc.contributor.authorAllison Wolf, M
dc.contributor.authorRader, Nathaniel A
dc.contributor.authorMiller, Olivia A
dc.contributor.authorShiflett, Morgane
dc.contributor.authorIzac, Jerilyn
dc.contributor.authorVarisco, David
dc.contributor.authorSen-Kilic, Emel
dc.contributor.authorCunningham, Casey
dc.contributor.authorCooper, Melissa
dc.contributor.authorCyphert, Holly A
dc.contributor.authorBarbier, Mariette
dc.contributor.authorMartinez, Ivan
dc.contributor.authorBevere, Justin R
dc.contributor.authorErnst, Robert K
dc.contributor.authorDamron, F Heath
dc.date.accessioned2022-03-25T12:46:40Z
dc.date.available2022-03-25T12:46:40Z
dc.date.issued2022-03-14
dc.identifier.urihttp://hdl.handle.net/10713/18343
dc.description.abstractSARS-CoV-2 is a viral respiratory pathogen responsible for the current global pandemic and the disease that causes COVID-19. All current WHO approved COVID-19 vaccines are administered through the muscular route. We have developed a prototype two-dose vaccine (BReC-CoV-2) by combining the Receptor Binding Domain (RBD) antigen, via conjugation to Diphtheria toxoid (EcoCRM®). The vaccine is adjuvanted with Bacterial Enzymatic Combinatorial Chemistry (BECC), BECC470. Intranasal (IN) administration of BreC-CoV-2 in K18-hACE2 mice induced a strong systemic and localized immune response in the respiratory tissues which provided protection against the Washington strain of SARS-CoV-2. Protection provided after IN administration of BReC-CoV-2 was associated with decreased viral RNA copies in the lung, robust RBD IgA titers in the lung and nasal wash, and induction of broadly neutralizing antibodies in the serum. We also observed that BReC-CoV-2 vaccination administered using an intramuscular (IM) prime and IN boost protected mice from a lethal challenge dose of the Delta variant of SARS-CoV-2. IN administration of BReC-CoV-2 provided better protection than IM only administration to mice against lethal challenge dose of SARS-CoV-2. These data suggest that the IN route of vaccination induces localized immune responses that can better protect against SARS-CoV-2 than the IM route in the upper respiratory tract.en_US
dc.description.urihttps://doi.org/10.1038/s41541-022-00451-7en_US
dc.language.isoenen_US
dc.publisherSpringer Natureen_US
dc.relation.ispartofNPJ Vaccinesen_US
dc.rights© 2022. The Author(s).en_US
dc.titleIntranasal administration of BReC-CoV-2 COVID-19 vaccine protects K18-hACE2 mice against lethal SARS-CoV-2 challenge.en_US
dc.typeArticleen_US
dc.identifier.doi10.1038/s41541-022-00451-7
dc.identifier.pmid35288576
dc.source.journaltitleNPJ vaccines
dc.source.volume7
dc.source.issue1
dc.source.beginpage36
dc.source.endpage
dc.source.countryEngland


This item appears in the following Collection(s)

Show simple item record